Another example of the power of our Sf9/BV platform is our ability to produce influenza virus-like particles (VLPs) using similar techniques. However, instead of producing single-target protein nanoparticles, as with our Rabies vaccine, scientists incorporated the gene sequences of multiple immunogenic proteins, together with universal matrix (M1) assembly proteins, to produce more complex envelope particle vaccines. Our influenza VLP vaccines incorporate the genetic sequences of the strain specific hemagglutinin (HA) and neuraminidase (NA) surface proteins. Traditional egg-based vaccines contain meaningful levels of HA protein, but little to no NA or M1, which may make them less immunogenic and effective. The HA sequence in our VLPs is the same as in the wild-type virus and could prove to be more effective or immunogenic than influenza vaccines produced using egg or mammalian cell-lines, which alter HA. In addition, the NA and M1 in our VLPs may play a role in reducing the severity of the disease by inducing antibody responses and cell mediated immunity. NA and M1 are both highly conserved, and immunity to these viral components may help provide additional protection throughout an entire influenza season, even as strains mutate.